Inadequate detection of the FSHR complicates future research on extragonadal FSHR localization

IntroductionRecently, follicle stimulating hormone (FSH) through interaction with its receptor (FSHR) has been proposed to play a role in postmenopausal osteoporosis and cardiovascular disease, rather than the loss of estrogen. To explore this hypothesis, unravelling which cells express extragonadal FSHR on protein level is key. MethodsWe used two commercial anti-FSHR antibodies and validated them by performing immunohistochemistry on positive (ovary, testis) and negative controls (skin). ResultsThe monoclonal anti-FSHR antibody could not identify the FSHR in ovary or testis. The polyclonal anti-FSHR antibody stained the granulosa cells (ovary) and Sertoli cells (testis), yet there was equally intense staining of other cells/extracellular matrix. Furthermore, the polyclonal anti-FSHR antibody also stained skin tissue extensively, suggesting that the antibody stains more than just FSHR. DiscussionThe findings in this study may add accuracy to literature on extragonadal FSHR localization and warrants attention to the use of inadequate anti-FSHR antibodies to value the potential role of FSH/FSHR in postmenopausal disease.

Automated summary

Recently, the role of follicle stimulating hormone receptor (FSHR) in postmenopausal osteoporosis and cardiovascular disease has been proposed. However, it is crucial to determine the expression of extragonadal FSHR on a protein level. In this study, two commercial anti-FSHR antibodies were validated and their specificity was assessed by immunohistochemistry. The findings highlight the need for accurate evaluation of FSH/FSHR in postmenopausal disease using appropriate antibodies.